

REPÚBLICA DE COLOMBIA
SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

Resolución N° 411

Ref. Expediente N° NC2017/0003838

Por la cual se otorga una Patente de Invención

EL SUPERINTENDENTE DE INDUSTRIA Y COMERCIO
en ejercicio de sus facultades legales, en especial de las conferidas en el numeral 26 del artículo 3° del Decreto 4886 de 2011, y

CONSIDERANDO:

PRIMERO: Que mediante escrito radicado en esta Superintendencia el 20 de abril de 2017, con el N° NC2017/0003838, por SIGNAL PHARMACEUTICALS LLC, entró a fase nacional la solicitud de patente de invención titulada “COMPUESTOS DE AMINOPURINA SUSTITUIDA, COMPOSICIONES DEL MISMO, Y MÉTODOS DE TRATAMIENTO CON LOS MISMOS”, que corresponde a la solicitud internacional PCT/US2015/053941 del 5 de octubre de 2015.

SEGUNDO: Que la solicitud fue publicada en la Gaceta de la Propiedad Industrial N° 798 el 11 de julio de 2017, sin que se hubieran presentado oposiciones por parte de terceros.

TERCERO: Que realizado el examen de fondo mediante Oficio N° 2915, notificado el 22 de mayo de 2019, se requirió al solicitante en los términos del artículo 45 de la Decisión 486 de la Comisión de la Comunidad Andina para que presentara respuesta a las observaciones de carácter técnico, relacionadas con la patentabilidad o cumplimiento de los requisitos establecidos por esta Decisión para la concesión de la patente.

CUARTO: Que el solicitante mediante escrito radicado bajo el N° NC2017/0003838 el 20 de agosto de 2019, respondió oportunamente el requerimiento formulado y presentan las reivindicaciones 1 a 40 que reemplazan las originalmente presentadas, atendiendo de esta manera las observaciones efectuadas en el examen de fondo. Se acepta este último capítulo reivindicatorio presentado, comoquiera que se ajusta a las prescripciones contenidas en el artículo 34 de la Decisión 486.

QUINTO: Que en virtud de lo dispuesto en el artículo 14 de la Decisión 486 expedida por la Comisión de la Comunidad Andina *“Los países miembros otorgarán patentes para las invenciones, sean de producto o de procedimiento, en todos los campos de la tecnología, siempre que sean nuevas, tengan nivel inventivo y sean susceptibles de aplicación industrial.”*

SEXTO: Que en el presente caso las reivindicaciones 1 al 40 incluidas en el radicado bajo el N° NC2017/0003838 el 20 de agosto de 2019, cumplen los requisitos indicados en el considerando anterior, toda vez que refieren a un compuesto derivado de purina útil para el tratamiento de melanomas, que difiere del estado de la técnica más cercano, WO2006076595, en la sustitución sobre el grupo amino en la posición 2 del anillo de aminopurina-8-halofenil-9-ciclohexan-carboxamida. Adicionalmente, estas diferencias no se encuentran sugeridas en el estado de la técnica y, como consecuencia de ello, se



Resolución N° 411

Ref. Expediente N° NC2017/0003838

evidencia el efecto de inhibir melanoma con IC₅₀ menor a 250 nM. Sumado a lo anterior, la materia reivindicada, es susceptible de aplicación industrial.

En consecuencia, las reivindicaciones 1 a 40 cumplen los requisitos de novedad, nivel inventivo y aplicación industrial establecidos en la normatividad citada en precedencia y este Despacho encuentra procedente conceder para las mismas la patente solicitada.

SÉPTIMO: Que de acuerdo con la modificación presentada por el solicitante en el escrito radicado bajo el N° NC2017/0003838 el 20 de agosto de 2019 y teniendo en cuenta el objeto concedido, se modifica el título de la invención el cual quedará de la siguiente manera: “COMPUESTOS DERIVADOS DE 4-(9H-PURIN-9-IL)CICLOHEXANOCARBOXAMIDA Y SUS COMPOSICIONES, QUE SON ACTIVOS CONTRA MELANOMA”

Con fundamento en las anteriores consideraciones, el Superintendente de Industria y Comercio,

RESUELVE

ARTÍCULO PRIMERO: Otorgar patente de invención a la solicitud que entró en fase nacional en virtud del Tratado de Cooperación en Materia de Patentes (PCT), para la creación titulada:

“COMPUESTOS DERIVADOS DE 4-(9H-PURIN-9-IL)CICLOHEXANOCARBOXAMIDA Y SUS COMPOSICIONES, QUE SON ACTIVOS CONTRA MELANOMA”

Clasificación IPC: C07D 473/40

Reivindicaciones: 1 a 40 incluidas en el radicado bajo el N° NC2017/0003838 el 20 de agosto de 2019, de acuerdo al anexo 1.

Titular: SIGNAL PHARMACEUTICALS LLC

Domicilio: 10300 CAMPUS POINT DRIVE, SUITE 100 SAN DIEGO, CA 92121 ESTADOS UNIDOS DE AMÉRICA.

Inventores: Matthew ALEXANDER, Sogole BAHMANYAR, John Fredrerick BOYLAN, Joshua HANSEN, Dehua HUANG, Robert HUBBARD, Brandon JEFFY, Jim LEISTEN, Mehran MOGHADDAM, Raj K. RAHEJA, Heather RAYMON, Kimberly SCHWARZ, Marianne SLOSS, Eduardo TORRES, Tam Minh TRAN, Shuichan XU y Jingjing ZHAO.

Prioridad N° 06/10/2014, US (ESTADOS UNIDOS DE AMÉRICA), 62/060,339

Solicitud internacional N°: PCT/US2015/053941 **Fecha:** 5 de octubre de 2015.

Vigente desde: 5 de octubre de 2015

Hasta: 5 de octubre de 2035.

ARTÍCULO SEGUNDO: El titular tendrá los derechos y las obligaciones establecidos en la Decisión 486 de la Comisión de la Comunidad Andina y en las demás disposiciones legales vigentes sobre propiedad industrial, precisando que para mantener vigente la patente se



Resolución N° 411

Ref. Expediente N° NC2017/0003838

deberá cancelar la tasa anual de mantenimiento, conforme lo dispone el artículo 80 de la referida norma comunitaria.

ARTÍCULO TERCERO: Notificar el contenido de la presente resolución a SIGNAL PHARMACEUTICALS LLC, advirtiéndoles que contra ella procede el recurso de reposición, ante el Superintendente de Industria y Comercio, el cual podrá ser interpuesto en el momento de la notificación o dentro de los diez (10) días hábiles siguientes a ella.

NOTIFÍQUESE Y CÚMPLASE

Dada en Bogotá D.C., el 11 de marzo de 2020



ANDRÉS BARRETO GONZÁLEZ
SUPERINTENDENTE DE INDUSTRIA Y COMERCIO

Firmado digitalmente
por: ANDRES
BERNARDO BARRETO
GONZALEZ
Fecha: 2020.03.11
23:02:18 COT
Razón: Validez jurídica.
Ubicación: Bogotá,
Colombia.


Resolución N° 411

Ref. Expediente N° NC2017/0003838

ANEXO 1

REIVINDICACIONES CONCEDIDAS

1. Un compuesto de la fórmula (I):



(I)

o una sal, tautómero, estereoisómero o enantiómero farmacéuticamente aceptable del mismo,

caracterizado porque:

R¹ es heterociclilo no aromático sustituido o no sustituido;

R² es H o alquilo de C₁₋₃ sustituido o no sustituido;

R³ es fenilo, sustituido con uno, dos o tres halógenos, opcional y adicionalmente sustituido con uno, dos o tres sustituyentes independientemente seleccionados de alquilo de C₁₋₃ sustituido o no sustituido, CN, y -OR', en donde cada R' es independientemente alquilo de C₁₋₃ sustituido o no sustituido;

en donde cuando un grupo alquilo C₁₋₃ está sustituido, está sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de cloro; yodo; bromo; flúor; alquilo; hidroxilo; alcoxi; alcoxialquilo; amino; alquilamino; carboxi; nitro; ciano; tiol; tioéter; imina; imida; amidina; guanidina; enamina; aminocarbonilo; acilamino; fosfonato; fosfina; tiocarbonilo; sulfinilo; sulfona; sulfonamida; acilo; éster; urea; uretano; oxima; hidroxil amina; alcoxiamina; ariloxiamina; aralcoxiamina; N-óxido; hidracina; hidrazida; hidrazona; azida; isocianato; isotiocianato; cianato; tiocianato; B(OH)₂; y O(alquil)aminocarbonilo;

en donde cuando un grupo, otro que un grupo alquilo C₁₋₃ está sustituido, está sustituido con uno, dos o tres sustituyentes seleccionados del grupo que consiste de cloro; yodo; bromo; flúor; alquilo; hidroxilo; alcoxi; alcoxialquilo; amino; alquilamino; carboxi; nitro; ciano; tiol; tioéter; imina; imida; amidina; guanidina; enamina; aminocarbonilo; acilamino; fosfonato; fosfina; tiocarbonilo; sulfinilo; sulfona; sulfonamida; acilo; éster; urea; uretano; oxima; hidroxil amina; alcoxiamina; ariloxiamina; aralcoxiamina; N-óxido; hidracina; hidrazida; hidrazona; azida; isocianato; isotiocianato; cianato; tiocianato; oxo; B(OH)₂; O(alquil)aminocarbonilo; cicloalquilo, el cual puede ser monocíclico o policíclico fusionado o no fusionado; arilo o heteroarilo monocíclico o policíclico fusionado o no fusionado; ariloxi; aralquilo; heterociclilo; y heterociclilalcoxi; y en donde un grupo alquilo es un

Resolución N° 411

Ref. Expediente N° NC2017/0003838

hidrocarburo no cíclico de cadena lineal o ramificada saturada, parcialmente saturada o insaturada que tiene de 1 a 10 átomos de carbono;

en donde un grupo cicloalquilo es un grupo alquilo cíclico saturado o parcialmente saturado de 3 a 10 átomos de carbono que tiene un único anillo cíclico o múltiples anillos condensados o con puente;

en donde un grupo arilo es un grupo carbocíclico aromático de 6 a 14 átomos de carbono que tiene un solo anillo o múltiples anillos condensados;

en donde un grupo heteroarilo es un cicloalquilo aromático de 3 a 10 átomos de carbono que tiene un solo anillo cíclico o múltiples anillos condensados o con puente en los que de uno a cuatro de los átomos de carbono del anillo se reemplazan independientemente con un heteroátomo del grupo que consiste en O, S y N;

en donde un grupo aralquilo es un radical de la fórmula: -alquil-arilo; y

en donde un grupo heterociclilo es un cicloalquilo aromático o no aromático en el cual de uno a cuatro de los átomos de carbono del anillo se reemplazan independientemente con un heteroátomo del grupo que consiste en O, S y N.


2. El compuesto de la reivindicación 1, caracterizado porque R¹ es un heterociclilo no aromático sustituido o no sustituido seleccionado de oxetanilo, tetrahydrofuranilo, tetrahidropiranilo, tetrahydro-tiopirandióxido, piperidilo, oxepanilo u oxaespiroheptilo.
3. El compuesto de la reivindicación 1, caracterizado porque R¹ se sustituye con uno, dos o tres sustituyentes independientemente seleccionados de halógeno, OR, SO₂R⁴, C(=O)R⁵, C(=O)OR⁶, C(=O)NRR⁷, alquilo de C₁₋₃, arilo o heteroarilo, en donde cada R es independientemente H o alquilo de C₁₋₃; R⁴ es alquilo de C₁₋₃, o arilo; R⁵ es alquilo de C₁₋₃; R⁶ es alquilo de C₁₋₆; y R⁷ es alquilo de C₁₋₃, o arilo.
4. El compuesto de la reivindicación 1, caracterizado porque R¹ es oxetanilo, tetrahydrofuranilo, tetrahidropiranilo, tetrahydro-tiopirandióxido, piperidilo, oxepanilo u oxaespiroheptilo, opcionalmente sustituido con uno, dos o tres sustituyentes independientemente seleccionados de F, OH, SO₂CH₃, SO₂-tosilo, C(=O)CH₃, C(=O)OCH₃, C(=O)O-ter-butilo, C(=O)O-isopropilo, C(=O)NHCH₃, C(=O)NH-fenilo, metilo, etilo, isopropilo, CH₂OH, fenilo, piridilo, o bencilo.
5. El compuesto de la reivindicación 1, caracterizado porque R² es H.
6. El compuesto de la reivindicación 1, caracterizado porque R² es CH₃.
7. El compuesto de la reivindicación 1, caracterizado porque R³ es fenilo orto-halógeno sustituido.
8. El compuesto de la reivindicación 1, caracterizado porque R³ es fenilo para-halógeno sustituido.



Resolución N° 411

Ref. Expediente N° NC2017/0003838

9. El compuesto de la reivindicación 1, caracterizado porque R^3 es fenilo para-CN sustituido.
10. El compuesto de la reivindicación 1, caracterizado porque R^3 es fenilo orto, orto-dihalógeno sustituido.
11. El compuesto de la reivindicación 1, caracterizado porque R^3 es fenilo orto, para-dihalógeno sustituido.
12. El compuesto de la reivindicación 1, caracterizado porque R^3 es fenilo de 2,4,6-trihalógeno sustituido.
13. El compuesto de la reivindicación 1, caracterizado porque R^3 es fenilo orto-halógeno, para-CN sustituido.
14. El compuesto de la reivindicación 1, caracterizado porque R^3 es



caracterizado porque

cada Hal es independientemente halógeno;

cada R^8 es independientemente alquilo de C_{1-3} sustituido o no sustituido, CN u OR';

cada R' es independientemente alquilo de C_{1-3} sustituido o no sustituido;


m es 1-3;

y p es 0-2.

15. El compuesto de la reivindicación 14, caracterizado porque cada Hal es independientemente Cl o F.
16. El compuesto de la reivindicación 14, caracterizado porque cada R^8 es independientemente CH_3 , CF_3 , CN u OCH_3 .
17. El compuesto de la reivindicación 14, caracterizado porque m es 2 o 3.
18. El compuesto de la reivindicación 14, caracterizado porque p es 0 o 1.
19. El compuesto de la reivindicación 14, en donde R^3 es

Resolución N° 411

Ref. Expediente N° NC2017/0003838



y cada Hal es independientemente halógeno.

20. El compuesto de la reivindicación 19, caracterizado porque cada Hal es independientemente F o Cl.

21. Un compuesto, caracterizado porque el compuesto es:

(1s,4s)-4-(8-(3-clorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexano carboxamida;

(1s,4s)-4-(8-(3-clorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)ciclohexano carboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,4-difluorofenilamino)-9H-purin-9-il) ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-clorofenilamino)-2-(4-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-difluorofenilamino)-2-(3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-difluorofenilamino)-2-(1-metilciclobutilamino)-9H-purin-9-il) ciclohexanocarboxamida;

(1s,4s)-4-(2-(tert-butilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il) ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-difluorofenilamino)-2-((3R,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4-metiltetrahidro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenil amino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-2-fluorofenilamino)-2-(4-metiltetrahidro-2H-piran-4-il amino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(tetrahidro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-difluorofenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(2-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((3R,4R)-3-metiltetrahydro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-difluorofenilamino)-2-((3R,4R)-3-metiltetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-6-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-diclorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-clorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3,4-diclorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(5-cloro-2-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-2-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,5-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-2-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(tetrahydro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,3-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-diclorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-5-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;



Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(2-cloro-4-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-fluoro-2-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-bromo-2-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-fluoro-4-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-(trifluorometil)fenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-fluoro-2-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(tetrahydro-2H-piran-4-ilamino)-8-(2,3,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-1-metil-4-(2-(tetrahydro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-(ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

- (1s,4s)-4-(8-(2,6-difluorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(2-(ciclobutilamino)-8-(2,6-diclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,6-diclorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(2-(ciclopentilamino)-8-(2,6-diclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(2-(oxetan-3-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,6-diclorofenilamino)-2-(oxetan-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-(oxetan-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(2-(tetrahydro-2H-piran-4-ilamino)-8-(2,4,5-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(2-(isopropilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(4-cloro-2-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-cloro-3-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,3-diclorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-fluoro-6-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;



Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(5-cloro-2,4-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(tetrahydro-2H-piran-4-ilamino)-8-(2,4,5-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(tetrahydro-2H-piran-4-ilamino)-8-(2,3,4-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-3-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,5-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2-fluoro-5-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(tetrahydro-2H-piran-4-ilamino)-8-(2,3,4-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-fluoro-6-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2-fluoro-6-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-tetrahydrofuran-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-((1r,4r)-4-metoxiciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-((1r,4r)-4-hidroxiciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-6-fluoro-2-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,5-dicloro-4-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(2,3-dicloro-4-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-3-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,3-difluoro-4-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-3-fluoro-4-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,3-dicloro-4-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-difluoro-6-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-tetrahydrofuran-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4,4-difluorociclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-3-fluoro-2-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-3,6-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-6-fluoro-3-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-((1,1-dioxidotetrahydro-2H-tiopiran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)ciclohexano-1-carboxamida;

(1s,4s)-4-(8-(2-clorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,4-diclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2-fluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-diclorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-fluorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

- (1s,4s)-4-(2-(isopropilamino)-8-(2,3,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-cloro-4,5-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-cloro-4,5-dimetilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(4-cloro-2-fluoro-3-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,4-dicloro-6-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,3-dicloro-6-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,4-dicloro-5-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,5-difluoro-4-metilfenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-(1-(piridin-3-il)piperidin-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-(1-fenilpiperidin-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,4,6-triclorofenilamino)-2-(2,2,2-trifluoroetilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(2-(ciclobutilmetilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(2-((R)-tetrahydro-2H-piran-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(3,4-dicloro-2-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(6-cloro-2,3-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-(1-(metilsulfonil)piperidin-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(2,6-difluoro-4-metilfenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-metilfenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((R)-1-hidroxibutan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(3R,4S)-tert-butil 4-(9-((1s,4R)-4-carbamoilciclohexil)-8-(2,4,6-trifluorofenilamino)-9H-purin-2-ilamino)-3-fluoropiperidina-1-carboxilato;

(3R,4S)-tert-butil 4-(9-((1s,4R)-4-carbamoilciclohexil)-8-(2,6-difluorofenilamino)-9H-purin-2-ilamino)-3-fluoropiperidina-1-carboxilato;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((R)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((R)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((R)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((S)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((S)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-hidroxiбутан-2-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3R,4S)-3-fluoropiperidin-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,3-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-2-fluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,3,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-1-metoxipropan-2-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-1-hidroxiбутан-2-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-((S)-1-hidroxiбутан-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((S)-1-hidroxiбутан-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((S)-1-hidroxiбутан-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((S)-1-hidroxiбутан-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-1-hidroxiбутан-2-ilamino)-8-(2,3,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1R,4s)-4-(8-(2,4-diclorofenilamino)-2-((S)-1-hidroxiбутан-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(3-cloro-2-fluorofenilamino)-2-((S)-1-hidroxiбутан-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-1-hidroxiбутан-2-ilamino)-8-(2,3,4-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-2-hidroxiпропилamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-diclorofenilamino)-2-((S)-1-hidroxiбутан-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-1-hidroxiбутан-2-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(3R,4S)-tert-butil 4-(9-((1s,4R)-4-carbamoilciclohexil)-8-(4-cloro-2,6-difluorofenilamino)-9H-purin-2-ilamino)-3-fluoropiperidina-1-carboxilato;

(1s,4s)-4-(8-((4-cloro-2,6-difluorofenil)amino)-2-((1,1-dioxidotetrahidro-2H-tiopiran-4-il)amino)-9H-purin-9-il)ciclohexano-1-carboxamida;

(1s,4s)-4-(8-((2,4-dicloro-6-fluorofenil)amino)-2-((1,1-dioxidotetrahidro-2H-tiopiran-4-il)amino)-9H-purin-9-il)ciclohexano-1-carboxamida;

(R)-tert-butil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4,6-trifluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-tert-butil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-tert-butil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-diclorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-tert-butil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2-cloro-4,6-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-tert-butil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(4-cloro-2,6-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-tert-butil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4,6-triclorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(1R,4s)-4-(2-((S)-1-hidroxiпропан-2-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-1-hidroxiпропан-2-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((S)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-difluorofenilamino)-2-((S)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-diclorofenilamino)-2-((S)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((S)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-diclorofenilamino)-2-((S)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(5-cloro-2-fluorofenilamino)-2-((S)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(3-cloro-2-fluorofenilamino)-2-((S)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(2,6-diclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(2-cloro-4,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(4-cloro-2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4-hidroxitetrahidrofuran-3-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-diclorofenilamino)-2-(4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4-hidroxitetrahidrofuran-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;



Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(4-hidroxitetrahydrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(4-hidroxitetrahydrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((R)-tetrahydro-2H-piran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((R)-tetrahydro-2H-piran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((R)-tetrahydro-2H-piran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-tetrahydro-2H-piran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-diclorofenilamino)-2-(4-hidroxitetrahydrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-2-fluorofenilamino)-2-(4-hidroxitetrahydrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(4-cloro-2,3-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(3-cloro-2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(1-acetilpiperidin-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(1-acetilpiperidin-4-ilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((R)-tetrahydrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((S)-tetrahidro-2H-piran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((S)-tetrahidro-2H-piran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((S)-tetrahidro-2H-piran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-((1-(hidroximetil)ciclopropil)metilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1-(hidroximetil)ciclopropil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R)-3-hidroxiciclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-difluorofenilamino)-2-((1R,3R)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,3R)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-diclorofenilamino)-2-((1R,3R)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R)-3-hidroxiciclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3R)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-((1R,3R)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-((1R,3R)-3-hidrox ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R)-3-hidrox ciclopentilamino)-8-(2,3,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-diclorofenilamino)-2-((1R,3R)-3-hidrox ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R)-3-hidrox ciclopentilamino)-8-(2,3,4-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((R)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((R)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(3,3-difluorociclobutilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(3,3-difluorociclobutilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(3,3-difluorociclobutilamino)-8-(2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(3,3-difluorociclobutilamino)-8-(2,3,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;



Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-diclorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-2-fluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,5-difluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4,4-difluorociclohexilamino)-8-(2,3,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-diclorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((S)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((S)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((S)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((S)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((S)-tetrahidro-2H-piran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3R,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-difluorofenilamino)-2-((3R,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-cianofenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,2R)-2-hidroxiciclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(2,6-difluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-diclorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,2R)-2-hidroxiciclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,2R)-2-hidroxiciclopentilamino)-8-(2,3,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-diclorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(5-cloro-2-fluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(3-cloro-2-fluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,2R)-2-hidroxiciclopentilamino)-8-(2,3,4-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,5-difluorofenilamino)-2-((1R,2R)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,2S)-2-hidroxiciclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-difluorofenilamino)-2-((1S,2S)-2-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1R,4s)-4-(8-(2,6-diclorofenilamino)-2-((1S,2S)-2-hidrox ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1S,2S)-2-hidrox ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,2S)-2-hidrox ciclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1S,2S)-2-hidrox ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1S,2S)-2-hidrox ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-((1S,2S)-2-hidrox ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-difluorofenilamino)-2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3R,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-((1r,3r)-3-hidrox ciclobutilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-diclorofenilamino)-2-((1r,3r)-3-hidrox ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-((1r,3r)-3-hidrox ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1r,3r)-3-hidrox ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1r,3r)-3-hidrox ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1r,3r)-3-hidrox ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;



Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-((1r,3r)-3-hidroxiciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-((1r,3r)-3-hidroxiciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-2,5-difluorofenilamino)-2-((1r,3r)-3-hidroxiciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4,4-difluorociclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4,4-difluorociclohexilamino)-8-(2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(1-(metilsulfonil)piperidin-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-diclorofenilamino)-2-(1-(metilsulfonil)piperidin-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(1-(metilsulfonil)piperidin-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(1-(metilsulfonil)piperidin-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(1-(metilsulfonil)piperidin-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(1-(metilsulfonil)piperidin-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-(1-(metilsulfonil)piperidin-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-diclorofenilamino)-2-(1-(metilsulfonil)piperidin-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-((1r,3r)-3-hidroxiciclobutilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1r,3r)-3-hidroxiciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(2-((3R,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-difluorofenilamino)-2-((3R,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-difluorofenilamino)-2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((3R,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-((1s,3s)-3-hidroxiciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3S,4R)-4-hidroxitetrahidrofuran-3-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((3S,4R)-4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3S,4R)-4-hidroxitetrahidrofuran-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((3R,4S)-4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((3R,4S)-4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((3R,4S)-4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-((3S,4R)-4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-((3S,4R)-4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1R,4s)-4-(8-(2,4-diclorofenilamino)-2-((3S,4R)-4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(5-cloro-2-fluorofenilamino)-2-((3S,4R)-4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,5-difluorofenilamino)-2-((3R,4S)-4-hidroxitetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1s,3s)-3-hidroxiciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-((1s,3s)-3-hidroxiciclobutilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1s,3s)-3-hidroxiciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-((1S,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-difluorofenilamino)-2-((1S,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-diclorofenilamino)-2-((1S,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1S,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3S)-3-hidroxiciclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3S)-3-hidroxiciclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3S)-3-hidroxiciclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3S)-3-hidroxiciclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-(sec-butilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-(sec-butilamino)-8-(2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

- (1R,4s)-4-(2-(sec-butilamino)-8-(2,6-diclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(2-(sec-butilamino)-8-(2-cloro-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(2-(sec-butilamino)-8-(2-cloro-4,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(2-(sec-butilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(2-(sec-butilamino)-8-(3-cloro-2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(2,6-difluorofenilamino)-2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(2,6-diclorofenilamino)-2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(2-((1R,3S)-3-hidroxiciclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(2,6-difluorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(2,6-diclorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(2-((1R,3S)-3-hidrox ciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-8-(2,3,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-((1R,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-((1R,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,5-difluorofenilamino)-2-((1R,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3S)-3-hidrox ciclohexilamino)-8-(2,3,4-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-(trifluorometoxi)fenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-(ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1R,4s)-4-(8-(2,6-diclorofenilamino)-2-((1S,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1S,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1S,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3R)-3-hidroxiciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1S,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-((1S,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1S,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-((1S,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-ciano-2,3-difluorofenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,3-difluoro-4-metoxifenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R)-3-hidroxi-4,4-dimetilciclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-difluorofenilamino)-2-((1R,3R)-3-hidroxi-4,4-dimetilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-diclorofenilamino)-2-((1R,3R)-3-hidroxi-4,4-dimetilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-((1R,3R)-3-hidroxi-4,4-dimetilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,3R)-3-hidroxi-4,4-dimetilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3R)-3-hidroxi-4,4-dimetilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;



Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(2-((1R,3R)-3-hidroxi-4,4-dimetilciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,3R)-3-hidroxi-4,4-dimetilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,3R)-3-hidroxi-4,4-dimetilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(3-cloro-2,6-difluorofenilamino)-2-((1R,3R)-3-hidroxi-4,4-dimetilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-diclorofenilamino)-2-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-6-fluoro-4-(trifluorometil)fenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-((S)-1-hidroxibutan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4,6-trifluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-diclorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2-cloro-6-fluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2-cloro-4,6-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(4-cloro-2,6-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4,6-triclorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(4-cloro-2,3-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(3-cloro-2,6-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,3,4-trifluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(1S,4s)-4-(2-((1R,3R)-3-hidroxiciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-diclorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R)-3-hidroxiciclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-difluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-diclorofenilamino)-2-((1R,3S)-3-hidroxi-3-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,3S)-3-hidroxi-3-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3S)-3-hidroxi-3-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,3S)-3-hidroxi-3-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,3S)-3-hidroxi-3-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-fluorofenilamino)-2-((1R,3S)-3-hidroxi-3-metilciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((S)-1-hidroxibutan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((S)-1-hidroxibutan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3S)-3-hidroxicicloheptilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-diclorofenilamino)-2-((1R,3S)-3-hidroxicicloheptilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-6-fluorofenilamino)-2-((1R,3S)-3-hidroxicicloheptilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,3S)-3-hidroxicicloheptilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3S)-3-hidroxicicloheptilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3S)-3-hidroxicicloheptilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-((1R,3S)-3-hidroxicicloheptilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-(isopropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-(trifluorometil)fenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-3-cianofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3R)-3-hidroxicicloheptilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((2S,4R)-2-(hidroximetil)tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((2S,4R)-2-(hidroximetil)tetrahydro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(3-ciano-2,6-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1S,3S)-3-hidroxicicloheptilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1S,3S)-3-hidroxicicloheptilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2,2-difluoro-3-hidroxipropilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(2,2-difluoro-3-hidroxipropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(2,2-difluoro-3-hidroxipropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(2,2-difluoro-3-hidroxipropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-(trifluorometil)fenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1R,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1R,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-((1R,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3S)-3-hidrox ciclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1S,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1S,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3S)-3-hidrox ciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1S,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,3-difluorofenilamino)-2-((1S,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1S,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,5-difluorofenilamino)-2-((1S,3S)-3-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,2R)-2-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,2R)-2-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,2R)-2-hidrox ciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,2R)-2-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,2R)-2-hidrox ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-1,1,1-trifluoro-3-hidroxipropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((R)-1,1,1-trifluoro-3-hidroxipropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1r,4r)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-1-metil-4-(2-(tetrahydro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1r,4r)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4r)-4-(8-(2,6-dicloro-4-(trifluorometil)fenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4r)-4-(2-((S)-1-hidroxipropan-2-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(3-hidroxi-2,2-dimetilpropilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,2S)-2-hidroxiciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4r)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(2-(ciclopentilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(2-(ciclopentilamino)-8-(2,6-dicloro-4-(trifluorometil)fenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1r,4r)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(2-(ciclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(2-(ciclopentilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(2-(ciclopentilamino)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1r,4r)-4-(2-(ciclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((3S,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((3R,4S)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((3R,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((3S,4S)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((3S,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3R,4S)-3-metiltetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((3R,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3S,4S)-3-metiltetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((3S,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((3R,4S)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((3R,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((3S,4S)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((3R,4S)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((3R,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((3S,4S)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3R,4S)-3-metiltetrahidro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((3S,4S)-3-metiltetrahidro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,2R)-2-hidroxiciclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1S,2R)-2-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,2R)-2-hidroxiciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1S,2R)-2-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1S,2R)-2-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1S,2R)-2-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((R)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1S,2R)-2-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((R)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-1-metil-4-(2-(tetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(2,6-dicloro-4-(trifluorometil)fenilamino)-2-((R)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-((R)-tetrahidrofuran-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-tetrahidrofuran-3-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(1-morfolinopropan-2-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((3S,4R)-3-metiltetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((3S,4R)-3-metiltetrahydro-2H-piran-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(oxepan-4-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(oxepan-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(oxepan-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(oxepan-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(oxepan-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(oxepan-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-(oxepan-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(oxepan-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-(trifluorometil)fenilamino)-2-(oxepan-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-3,3-difluorociclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-1-hidroxipropan-2-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-1-hidroxipropan-2-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-(trifluorometil)fenilamino)-2-((S)-1-hidroxipropan-2-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(oxepan-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,6-dicloro-4-(trifluorometil)fenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3S)-3-hidroxiciclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3S)-3-hidroxiciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(2,6-dicloro-4-(trifluorometil)fenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(2-cloro-4-ciano-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(2-oxaspiro[3.3]heptan-6-ilamino)-8-(4-ciano-2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-(trifluorometil)fenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(3,3-difluorociclobutilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(3,3-difluorociclobutilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-(trifluorometil)fenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((S)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((R)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((S)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((R)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((S)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((R)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((S)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-3,3-difluorociclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-((S)-3,3-difluorociclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-(trifluorometoxi)fenilamino)-2-((1R,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-(trifluorometoxi)fenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,6-dicloro-4-(trifluorometoxi)fenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,6-dicloro-4-(trifluorometoxi)fenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(ciclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-(ciclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,6-dicloro-4-(trifluorometil)fenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(ciclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(2-(ciclobutilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(ciclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3S)-3-hidroxiciclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1S,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3S)-3-hidroxiciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1S,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1S,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1S,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1S,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1S,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R)-3-hidroxiciclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R)-3-hidroxiciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1R,4s)-4-(2-((1S,3R)-3-hidrox ciclohexilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1S,3R)-3-hidrox ciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3R)-3-hidrox ciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1S,3R)-3-hidrox ciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1S,3R)-3-hidrox ciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1S,3R)-3-hidrox ciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1S,3R)-3-hidrox ciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R)-3-hidrox ciclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1R,3R)-3-hidrox ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(2-((1R,3R)-3-hidrox ciclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1R,3R)-3-hidrox ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1R,3R)-3-hidrox ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1R,3R)-3-hidrox ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1R,3R)-3-hidrox ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1R,3R)-3-hidrox ciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3S)-3-hidroxiciclopentilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((1S,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(2-((1S,3S)-3-hidroxiciclopentilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1S,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((1S,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((1S,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1S,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1S,3S)-3-hidroxiciclopentilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(2-(((1S,2S)-2-hidroxiciclohexil)metilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(((1S,2S)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(2-(((1S,2S)-2-hidroxiciclohexil)metilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(((1S,2S)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(((1S,2S)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(((1S,2S)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(((1S,2S)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

- (1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(((1S,2S)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(((1S,2R)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(2-(((1S,2R)-2-hidroxiciclohexil)metilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(((1S,2R)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(((1S,2R)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-(((1S,2R)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(((1S,2R)-2-hidroxiciclohexil)metilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(3,3-difluorociclobutilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(4-(2,5-dioxopirrolidin-1-il)ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(4-(2,5-dioxopirrolidin-1-il)ciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1s,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;
- (1s,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-(tetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(2-(4-(1,2,4-oxadiazol-5-il)ciclohexilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4-(1,2,4-oxadiazol-5-il)ciclohexilamino)-8-(2-cloro-4,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4-(1,2,4-oxadiazol-5-il)ciclohexilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4-(1,2,4-oxadiazol-5-il)ciclohexilamino)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4-(1,2,4-oxadiazol-5-il)ciclohexilamino)-8-(2-cloro-4-ciano-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(4-(1,2,4-oxadiazol-5-il)ciclohexilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1R,3R)-3-hidroxiciclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1R,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1S,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1S,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((1S,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((1S,3S)-3-hidroxiciclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-bromo-2,6-diclorofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-bromo-2,6-diclorofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((3S,4S)-3-fluorotetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1s,4s)-4-(2-(ciclopentilamino)-8-(2,3-dicloro-4-cianofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,3-dicloro-4-cianofenilamino)-2-((S)-1-hidroxiopropan-2-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,3-dicloro-4-cianofenilamino)-2-(4,4-difluorociclohexilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,3-dicloro-4-cianofenilamino)-2-(tetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-((R)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((R)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((R)-3,3-difluorociclopentilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-(metilsulfonil)piperidin-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-1-(metilsulfonil)piperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((R)-1-(metilsulfonil)piperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((R)-1-(metilsulfonil)piperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((R)-1-(metilsulfonil)piperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4,6-triclorofenilamino)-9H-purin-2-ilamino)-N-metilpiperidina-1-carboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-2-ilamino)-N-metilpiperidina-1-carboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-2-ilamino)-N-metilpiperidina-1-carboxamida;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

(R)-metil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2-cloro-4-ciano-6-fluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(2-((R)-1-acetilpiperidin-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-acetilpiperidin-3-ilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-acetilpiperidin-3-ilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-acetilpiperidin-3-ilamino)-8-(4-cloro-2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((3S,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1R,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((3S,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((3S,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1R,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((3S,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-1-metil-4-(2-((3S,4R)-3-metiltetrahydro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((3S,4R)-3-fluorotetrahydro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(2-(3-(metilsulfonil)ciclobutilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-(3-(metilsulfonil)ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-(3-(metilsulfonil)ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-etilpiperidin-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((R)-1-etilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-1-etilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(2,6-dicloro-4-(trifluorometil)fenilamino)-2-(3-(metilsulfonil)ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1s,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-(3-(metilsulfonil)ciclobutilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-(trifluorometil)fenilamino)-2-((R)-1-etilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-isopropilpiperidin-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((R)-1-isopropilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((R)-1-isopropilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-1-isopropilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((R)-1-fenilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-fenilpiperidin-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((R)-1-fenilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-((R)-1-fenilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-fenilpiperidin-3-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((R)-1-fenilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-1-fenilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((R)-1-fenilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((R)-1-fenilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-bencilpiperidin-3-ilamino)-8-(2-cloro-4,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-bencilpiperidin-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-bencilpiperidin-3-ilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-bencilpiperidin-3-ilamino)-8-(2,6-dicloro-4-(trifluorometil)fenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-bencilpiperidin-3-ilamino)-8-(4-ciano-2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-bencilpiperidin-3-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-bencilpiperidin-3-ilamino)-8-(4-cloro-2,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-bencilpiperidin-3-ilamino)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-bencilpiperidin-3-ilamino)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

- (1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;
- (1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((3S,4R)-3-metiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida;
- (1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-3,3-dimetiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((3S,4S)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (1S,4s)-4-(2-((R)-3,3-dimetiltetrahidro-2H-piran-4-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;
- (R)-isopropil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2-cloro-4,6-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;
- (R)-isopropil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4,6-triclorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;
- (R)-isopropil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;
- (R)-isopropil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-dicloro-4-(trifluorometil)fenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;
- (R)-isopropil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(4-ciano-2,6-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;
- (R)-isopropil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4,6-trifluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;
- (R)-isopropil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(4-cloro-2,6-difluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;
- (R)-isopropil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;
- (R)-isopropil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;
- (R)-isopropil 3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2-cloro-4-ciano-6-fluorofenilamino)-9H-purin-2-ilamino)piperidina-1-carboxilato;
- (1S,4s)-4-(2-((R)-1-bencilpiperidin-3-ilamino)-8-(2-cloro-4-ciano-6-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

Resolución N° 411

Ref. Expediente N° NC2017/0003838

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2-cloro-4,6-difluorofenilamino)-9H-purin-2-ilamino)-N-fenilpiperidina-1-carboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4,6-triclorofenilamino)-9H-purin-2-ilamino)-N-fenilpiperidina-1-carboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-2-ilamino)-N-fenilpiperidina-1-carboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4,6-trifluorofenilamino)-9H-purin-2-ilamino)-N-fenilpiperidina-1-carboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(4-cloro-2,6-difluorofenilamino)-9H-purin-2-ilamino)-N-fenilpiperidina-1-carboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,4-dicloro-6-fluorofenilamino)-9H-purin-2-ilamino)-N-fenilpiperidina-1-carboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-2-ilamino)-N-fenilpiperidina-1-carboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2-cloro-4-ciano-6-fluorofenilamino)-9H-purin-2-ilamino)-N-fenilpiperidina-1-carboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((R)-3,3-dimetiltetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2-cloro-4,6-difluorofenilamino)-2-((R)-1-tosilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-tosilpiperidin-3-ilamino)-8-(2,4,6-triclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((R)-1-tosilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-((R)-1-tosilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-tosilpiperidin-3-ilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-cloro-2,6-difluorofenilamino)-2-((R)-1-tosilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((R)-1-tosilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((R)-1-tosilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;



Resolución N° 411

Ref. Expediente N° NC2017/0003838

(1S,4s)-4-(8-(2-cloro-4-ciano-6-fluorofenilamino)-2-((R)-1-tosilpiperidin-3-ilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(R)-3-(9-((1s,4S)-4-carbamoilciclohexil)-8-(2,6-dicloro-4-(trifluorometil)fenilamino)-9H-purin-2-ilamino)-N-metilpiperidina-1-carboxamida;

(1S,4s)-4-(2-((R)-1-acetilpiperidin-3-ilamino)-8-(2-cloro-4,6-difluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-acetilpiperidin-3-ilamino)-8-(2,6-dicloro-4-(trifluorometil)fenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-acetilpiperidin-3-ilamino)-8-(2,6-dicloro-4-fluorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(2-((R)-1-acetilpiperidin-3-ilamino)-8-(2,6-diclorofenilamino)-9H-purin-9-il)ciclohexanocarboxamida;

(1S,4s)-4-(8-(4-ciano-2,6-difluorofenilamino)-2-((3S,4R)-3-fluorotetrahidro-2H-piran-4-ilamino)-9H-purin-9-il)ciclohexanocarboxamida; or

(1R,4s)-4-(2-(((3R,4S)-3-fluorotetrahidro-2H-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)-1-metilciclohexano-1-carboxamida, o una sal, tautómero, estereoisómero o enantiómero farmacéuticamente aceptable de este.

22. Una composición farmacéutica caracterizada porque comprende una cantidad efectiva de un compuesto de la reivindicación 1 y un portador, excipiente o vehículo farmacéuticamente aceptable.
23. Un método *in vitro* para inhibir una quinasa en una célula que expresa dicha quinasa, caracterizado porque comprende poner en contacto dicha célula con una cantidad efectiva de un compuesto de la reivindicación 1.
24. Un método *ex vivo* para inhibir una quinasa en una célula que expresa dicha quinasa, caracterizado porque comprende poner en contacto dicha célula con una cantidad efectiva de un compuesto de la reivindicación 1.
25. Una composición farmacéutica caracterizada porque comprende una cantidad efectiva de un compuesto de la reivindicación 21 y un portador, excipiente o vehículo farmacéuticamente aceptable.
26. Un método *in vitro* para inhibir una quinasa en una célula que expresa dicha quinasa, caracterizado porque comprende poner en contacto dicha célula con una cantidad efectiva de un compuesto de la reivindicación 21.
27. Un método *ex vivo* para inhibir una quinasa en una célula que expresa dicha quinasa, caracterizado porque comprende poner en contacto dicha célula con una cantidad efectiva de un compuesto de la reivindicación 21.



Resolución N° 411

Ref. Expediente N° NC2017/0003838

28. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((S)-1-hidroxipropan-2-il amino)-9H-purin-9-il)ciclohexanocarboxamida.
29. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((S)-1-hidroxipropan-2-il amino)-9H-purin-9-il)-1-metilciclohexanocarboxamida.
30. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1R,4s)-4-(8-(2,6-dicloro-4-cianofenilamino)-2-((S)-1-hidroxipropan-2-il amino)-9H-purin-9-il)ciclohexanocarboxamida.
31. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1s,4s)-4-(2-(ciclobutilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)ciclohexanocarboxamida.
32. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1s,4s)-4-(2-(ciclobutilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida.
33. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1s,4s)-4-(2-(3,3-difluorociclobutilamino)-8-(2,4,6-trifluorofenilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida.
34. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1s,4s)-4-(2-(ciclopentilamino)-8-(2,6-dicloro-4-cianofenilamino)-9H-purin-9-il)ciclohexanocarboxamida.
35. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1S,4s)-4-(8-(2,6-dicloro-4-fluorofenilamino)-2-((R)-3,3-difluorociclopentil amino)-9H-purin-9-il)ciclohexanocarboxamida.
36. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1R,4s)-4-(2-(((3R,4S)-3-fluorotetrahydro-2H-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)-1-metilciclohexano-1-carboxamida.
37. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1R,4s)-4-(8-(2,4-dicloro-6-fluorofenilamino)-2-((1S,3R)-3-hidroxiciclohexilamino)-9H-purin-9-il)-1-metilciclohexanocarboxamida.
38. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1S,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)-1-metilciclohexano-1-carboxamida.
39. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1S,4s)-4-(8-((4-cloro-2,6-difluorofenil)amino)-2-(((3S,4R)-3-metiltetrahydro-2H-piran-4-il)amino)-9H-purin-9-il)ciclohexano-1-carboxamida.

Resolución N° 411

Ref. Expediente N° NC2017/0003838

40. El compuesto de la reivindicación 21, caracterizado porque el compuesto es (1s,4s)-4-(8-((4-cloro-2,6-difluorofenil)amino)-2-((tetrahidro-2H-piran-4-il)amino)-9H-purin-9-il)ciclohexano-1-carboxamida.

